Mr. Brook Riggins reports

THIOGENESIS ENGAGES BRISCO CAPITAL FOR INVESTOR RELATIONS

Thiogenesis Therapeutics Corp. has engaged Brisco Capital Partners Corp. to provide investor relations services.

Brisco will assist the company in expanding communications with shareholders, investors and the broader investment community to increase awareness of Thiogenesis and its development programs.

Brisco is a Calgary, Alberta-based, investor relations firm providing services to a number of public companies including business development, road shows, corporate communications and trade show advisory. Brisco currently owns no securities in the company.

The agreement is effective as of Sept. 1, 2026. Brisco will receive a monthly fee of $6,000 plus applicable taxes and 100,000 stock options exercisable at 50 cents per share for 36 months, vesting quarterly over one year. The agreement and option grant remain subject to TSX Venture Exchange acceptance.

Amendment to omnibus equity incentive plan

The company intends to amend its omnibus equity incentive plan by increasing the number of common shares reserved for issuance from 9,099,095 to 13,995,931 common shares. The plan is a fixed 20-per-cent security-based compensation plan that permits the grant of stock options, restricted share units and deferred share units. There are currently 5,125,000 awards outstanding under the plan, leaving 3,424,095 awards available for future grants.

The board of directors has determined that the remaining reserve is insufficient to meet the company's anticipated incentive compensation requirements. The proposed amendment would restore the plan reserve to 20 per cent of the company's current issued and outstanding share capital.

The amendment is subject to TSX-V acceptance and disinterested shareholder approval at the company's annual and special meeting of shareholders scheduled for Sept. 8, 2026.

About Thiogenesis Therapeutics Corp.

Based in San Diego, Calif., Thiogenesis Therapeutics is a clinical-stage biotechnology company developing sulphur-based therapeutics for rare diseases. The company's lead candidate, TTI-0102, is being developed for nephropathic cystinosis and primary mitochondrial diseases, including Leigh syndrome spectrum. Thiogenesis is advancing TTI-0102 through clinical development with the goal of addressing significant unmet medical needs in rare genetic disorders.

We seek Safe Harbor.